Beranda › Melanoma › Minnesota › Minneapolis
Uji klinis Melanoma di Minneapolis, MN
12 studi untuk Melanoma mencari peserta di lokasi sekitar Minneapolis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi jauhnya
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 mi jauhnya
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi jauhnya
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Menerima pesertaFase 3
- Allina Health Cancer Institute, Minneapolis
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Menerima pesertaFase 3
- University of Minnesota, Minneapolis
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Menerima pesertaFase 1/2
- Minnesota Oncology and Hematology PA, Minneapolis
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Menerima pesertaFase 2
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- dan 1 lainnya
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Menerima pesertaFase 1/2
- University of Minnesota/Masonic Cancer Center, Minneapolis
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Menerima pesertaFase 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi jauhnya
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Menerima pesertaFase 3
- University of Minnesota Medical Center, Minneapolis
Uji klinis Melanoma di kota lain
- Houston, TX59 studi
- New York City, NY38 studi
- Los Angeles, CA34 studi
- Nashville, TN33 studi
- Pittsburgh, PA31 studi
- Boston, MA26 studi
- Philadelphia, PA23 studi
- San Francisco, CA22 studi
- Atlanta, GA21 studi
- Durham, NC21 studi
- St. Louis, MO21 studi
- Columbus, OH21 studi
Studi lain di Minneapolis
- Kanker Payudara27 studi
- Kanker Paru Non-Sel Kecil26 studi
- Kanker Ovarium24 studi
- Kanker Prostat23 studi
- Kanker (semua jenis)22 studi
- Gagal Jantung21 studi
- Kanker Paru20 studi
- Leukemia Mieloid Akut20 studi
- Kanker Kolorektal19 studi
- Kanker Endometrium18 studi
- Penyakit Parkinson17 studi
- Penyakit Kardiovaskular15 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.